Loading...
Market
GSK stock price change within a week of Blenrep's approval in China
2
American Society of Hematology•San Diego•California•Belantamab Mafodotin•China•National Medical Products Administration•NMPA•Blenrep
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
GSK's Blenrep Reduces Death Risk by 42% in Blood Cancer Trial, Gains Priority Review in China
Dec 9, 2024, 06:36 PM
GSK has presented positive results from a Phase III clinical trial at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California. The trial evaluated the company's blood cancer treatment, Belantamab Mafodotin (Blenrep), showing a significant reduction in the risk of death by 42% for patients with relapsed or refractory multiple myeloma. This outcome suggests a potential revival for the drug, which was withdrawn from the market two years ago. Additionally, China’s National Medical Products Administration (NMPA) has accepted GSK's application for a combination therapy involving Blenrep, granting it priority review status for relapsed/refractory multiple myeloma, supported by the DREAMM-7 trial results.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Yes • 50%
No • 50%
Below $10 • 25%
$10 - $15 • 25%
$15 - $20 • 25%
Above $20 • 25%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Changes by less than 5% • 25%
Decreases • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
No significant change • 25%
Decrease • 25%
Stock price increases by over 20% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
